Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Greenphire and Ernst & Young Announce Strategic Partnership

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Partnership will combine eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young.

Greenphire has announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.

Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. - The US Sunshine Act).

This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology.

Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.

Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.

Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”

Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Greenphire Awards $35,000 to Three Health and Wellness Nonprofits
NO MORE received a donation of $20,000 to further its mission to end domestic violence and sexual assault.
Wednesday, June 25, 2014
Greenphire Appoints Senior Director of Business Development in Europe
Alex Livingstone brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company.
Thursday, October 10, 2013
Greenphire Named One of the Fastest-Growing U.S Companies
The company has been ranked in the 2013 Inc. Magazine 500 list of the fastest-growing private companies in the U.S.
Wednesday, August 21, 2013
Greenphire and Oracle to Work Together
New partnership to automate clinical trial planning, budgeting and payments.
Tuesday, June 25, 2013
Greenphire and IMS Health Announce Strategic Integration
Launch of strategic integration of eClinicalGPS and GrantPlan.
Friday, June 21, 2013
Greenphire's John Samar Named CFO of the Year Finalist
The Philadelphia Business Journal awards honour professionals who have displayed outstanding performance in their roles as corporate financial leaders.
Wednesday, May 29, 2013
Greenphire CEO Selected as Finalist in Ernst & Young Awards
CEO Sam Whitaker has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.
Friday, May 17, 2013
Greenphire Announces New London Office
Plans to facilitate expansion in Europe.
Tuesday, May 07, 2013
Greenphire Appoints UK-based Global Product Manager
Appointment of Rory O’Hare to facilitate European growth.
Thursday, February 21, 2013
Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration
The proposed legislation expected to be enacted by 2016.
Friday, July 27, 2012
Greenphire Appoints Chief Commercial Officer
Appointment of John M Blakeley to the role of Chief Commercial Officer.
Thursday, July 12, 2012
Greenphire and Merge Healthcare Form Exclusive Partnership
Partnership to integrate clinical payment and EDC platforms.
Wednesday, May 09, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!